Attending ESC 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
Official Registration
Visit Official Website ↗Strategic Context
Attend the world's foremost cardiology meeting to stay updated on the latest advancements and research in cardiovascular medicine. Experience transformation through practice, policy, and responsibility, connecting with leading experts and peers in the field.
Who Attends
Cardiologists, Clinical Researchers, Healthcare Professionals (HCPs)
We are tracking late-breaking trials on pulsed field ablation for atrial fibrillation, updated Lp(a) lowering data, and the revised heart failure guidelines. Our editorial team will be in Munich and will publish session reports and expert commentary throughout the congress.
Coverage from ESC 2026
Faster Heart Attack Rule-Out: Can PRESC1SE-MI Deliver on ED Efficiency?
A new strategy for ruling out myocardial infarction in emergency departments, using high-sensitivity troponin and clinical risk scores, demonstrated high safety and reduced length of stay.
Why Transthyretin Amyloid Cardiomyopathy Remains Underdiagnosed
Transthyretin amyloid cardiomyopathy (ATTR-CM) often presents with non-specific symptoms, leading to significant diagnostic delays and missed opportunities for early intervention.
Can Factor XIa Inhibitors Reduce Post-MI Bleeding Without Compromising Efficacy?
Factor XIa inhibitors aim to reduce thrombotic events in acute coronary syndrome patients while minimizing bleeding risk, a critical balance in post-MI care.
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?
Factor XIa inhibitors offer a novel antithrombotic strategy after myocardial infarction, aiming for reduced bleeding risk compared to current agents.
Eplontersen: Can a new RNAi therapy change ATTR-CM outcomes?
Eplontersen significantly reduced transthyretin protein levels and improved clinical endpoints in ATTR amyloid cardiomyopathy.
Aficamten: A New Path for Non-Obstructive Hypertrophic Cardiomyopathy?
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition with limited treatment options. The drug targets cardiac myosin, reducing contractility and improving symptoms.
Do Statins Still Benefit Patients Over 70 Without Prior CVD?
The STAREE trial investigated statin use for primary prevention in individuals over 70, challenging long-held assumptions about cardiovascular benefit in this age group.
Do Statins Prevent Dementia in Healthy Older Adults? STAREE Trial Weighs In
The STAREE trial investigated statin use in healthy adults over 70, finding no reduction in dementia incidence but a modest cardiovascular benefit.
ESC Congress 2026: The 59 Pivotal Trials You Need to Know
Fifty-nine pivotal trials will present at ESC Congress 2026, covering major cardiovascular disease areas from heart failure to arrhythmia.
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?
GLP-1 receptor agonists reduce cardiovascular risk in obese individuals with established CVD, but their benefit in primary prevention remains unclear.
Ruling Out Heart Attacks Faster: The PRESC1SE-MI Study's ED Impact
The PRESC1SE-MI study demonstrated a novel algorithm using high-sensitivity troponin I can safely rule out myocardial infarction in the emergency department within one hour.
Aficamten targets non-obstructive HCM, a disease with no approved drug
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition lacking specific approved therapies.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
Elevated lipoprotein(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease. Early identification and management are critical.